Assistance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Service de Médecine Interne 2, Sorbonne Université, Paris, France.
Assistance Publique Hôpitaux de Paris, Service d'Hématologie Biologique, Hôpital de la Pitié-Salpêtrière, Paris, France.
Eur J Neurol. 2019 Oct;26(10):1274-1280. doi: 10.1111/ene.13975. Epub 2019 Jun 24.
Neurosarcoidosis is a rare inflammatory disorder of unknown cause. The aim of this study was to evaluate the value of T/B lymphocyte population counts and the concentrations of the cytokines interleukin (IL) 6 and IL-10 in the cerebrospinal fluid (CSF) of neurosarcoidosis patients.
A retrospective study CSF biomarkers was conducted in patients with neurosarcoidosis who underwent CSF analysis between 2012 and 2017 as well as various control populations.
Forty-three patients with neurosarcoidosis, 14 with multiple sclerosis (MS) and 48 with other inflammatory disorders were analyzed. The CSF IL-6 levels were higher in sarcoidosis patients than in MS patients (median 8 vs. 3 pg/ml, P = 0.006). The CSF CD4/CD8 ratio was higher in sarcoidosis patients than in MS patients and in patients with other inflammatory disorders (median 3.18 vs. 2.36 and 2.10, respectively, P = 0.008). The CSF IL-6 level was higher in patients with active neurosarcoidosis than in non-active neurosarcoidosis patients (median 13 vs. 3 pg/ml, P = 0.0005). In patients with neurosarcoidosis, a CSF IL-6 concentration >50 pg/ml was associated with a higher risk of relapse or progression-free survival (hazard ratio 3.60; 95% confidence interval 1.78-23.14). A refractory neurosarcoidosis patient was treated with an anti-IL-6 monoclonal antibody that produced a complete neurological response.
The CSF CD4/CD8 ratio and IL-6 concentration are increased in neurosarcoidosis compared to MS and other inflammatory disorders. A CSF IL-6 concentration >50 pg/ml is associated with relapse or progression of neurosarcoidosis. IL-10 levels may be elevated in neurosarcoidosis.
神经结节病是一种病因不明的罕见炎症性疾病。本研究旨在评估 T/B 淋巴细胞群计数以及细胞因子白细胞介素(IL)6 和 IL-10 在神经结节病患者脑脊液(CSF)中的浓度的价值。
对 2012 年至 2017 年间进行 CSF 分析的神经结节病患者以及各种对照人群进行了回顾性 CSF 生物标志物研究。
分析了 43 例神经结节病患者、14 例多发性硬化症(MS)患者和 48 例其他炎症性疾病患者。与 MS 患者相比,神经结节病患者的 CSF IL-6 水平更高(中位数 8 与 3 pg/ml,P=0.006)。与 MS 患者和其他炎症性疾病患者相比,神经结节病患者的 CSF CD4/CD8 比值更高(中位数分别为 3.18 与 2.36 和 2.10,P=0.008)。与非活动神经结节病患者相比,活动神经结节病患者的 CSF IL-6 水平更高(中位数 13 与 3 pg/ml,P=0.0005)。在神经结节病患者中,CSF IL-6 浓度>50 pg/ml 与复发或无进展生存风险增加相关(危险比 3.60;95%置信区间 1.78-23.14)。一名难治性神经结节病患者接受了抗 IL-6 单克隆抗体治疗,产生了完全的神经学反应。
与 MS 和其他炎症性疾病相比,CSF CD4/CD8 比值和 IL-6 浓度在神经结节病中升高。CSF IL-6 浓度>50 pg/ml 与神经结节病的复发或进展相关。IL-10 水平可能在神经结节病中升高。